Table 5.

Comparison of 2 weeks treatment outcomes of darifenacin, oxybutynin, or placebo (Zinner et al 2005)

	Darifenacin (n=58) 15 mg QD	Oxybutynin (n=58) 5 mg TDS	Placebo (n=58)
Micturition/day	9.33	9.24	9.62
Incontinence episodes/week	10.93*	9.45*	14.64
Urgency episodes/day	7.95*	8.12*	8.71
Severity of urgency episode**	1.93*	1.89*	2.03

Notes: Evaluable patients (n=58). Values shown are means adjusted for sequence and period from the crossover analysis of variance;

^*p<0.05 vs placebo, accounting from multiplicity by least significant difference method;

^**1=mild, 2=moderate, 3=severe.

Abbreviations: QD, once daily; TDS, three times daily